Enasidenib Mesilate

4 trials 1 recruiting Orphan designation

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

1 Recruiting

3 Completed trials

4 Sponsors

14 Countries

Phase III

Phase II

Phase I/II

Phase III: 1 Phase II: 1 Phase I/II: 2

Oversight events:

1 serious breach across 1 trial

View oversight register →

Indications tested

Myelodysplastic syndrome 1

Sponsors using this IMP

Celgene Corp. 1 Groupe Francophone Des Myelodysplasies 1 Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting 1 Institut Gustave Roussy 1

All trials

4 total

AcSé-ESMART: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors Recruiting

2024-514791-40-00 Phase I/II 5 countries Institut Gustave Roussy
Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio… Ended

2022-502832-37-00 Phase III 12 countries Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
study of the efficacy of treatment with AG-221 in patients with myelodysplastic syndrome and mutation IDH2 Ended

2024-513858-29-01 Phase II 2 countries Groupe Francophone Des Myelodysplasies
A clinical trial to evaluate the safety and effectiveness of a combination of either AG-12or AG-221 tablets with azacitidine injections in p… Ended

2024-511722-31-00 Phase I/II 4 countries Celgene Corp.

Showing 1–4 of 4 trials

← All drugs A–Z